Adjuvant interferon-alpha for melanoma revisited: news from old and new studies

C. J. Punt; A. M. Eggermont

doi:https://doi.org/10.1023/A:1013592219007

Adjuvant interferon-alpha for melanoma revisited: news from old and new studies

C. J. Punt, A. M. Eggermont

Other Departments

Research output: Contribution to journal › Review article › Academic › peer-review

23 Citations (Scopus)

Abstract

Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNalpha) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNalpha, the duration of IFNalpha administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNalpha does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNalpha trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNalpha is still immature. Therefore currently the routine use of IFNalpha cannot be recommended outside the scope of clinical trials

Original language	English
Pages (from-to)	1663-1666
Journal	Annals of Oncology
Volume	12
Issue number	12
DOIs	https://doi.org/10.1023/A:1013592219007
Publication status	Published - 2001

Access to Document

https://doi.org/10.1023/A:1013592219007

Cite this

@article{1e0b94e9081b457081f1994b9c6f560d,

title = "Adjuvant interferon-alpha for melanoma revisited: news from old and new studies",

abstract = "Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNalpha) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNalpha, the duration of IFNalpha administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNalpha does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNalpha trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNalpha is still immature. Therefore currently the routine use of IFNalpha cannot be recommended outside the scope of clinical trials",

author = "Punt, {C. J.} and Eggermont, {A. M.}",

year = "2001",

doi = "https://doi.org/10.1023/A:1013592219007",

language = "English",

volume = "12",

pages = "1663--1666",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Adjuvant interferon-alpha for melanoma revisited: news from old and new studies

AU - Punt, C. J.

AU - Eggermont, A. M.

PY - 2001

Y1 - 2001

N2 - Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNalpha) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNalpha, the duration of IFNalpha administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNalpha does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNalpha trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNalpha is still immature. Therefore currently the routine use of IFNalpha cannot be recommended outside the scope of clinical trials

AB - Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNalpha) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNalpha, the duration of IFNalpha administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNalpha does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNalpha trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNalpha is still immature. Therefore currently the routine use of IFNalpha cannot be recommended outside the scope of clinical trials

U2 - https://doi.org/10.1023/A:1013592219007

DO - https://doi.org/10.1023/A:1013592219007

M3 - Review article

C2 - 11843241

SN - 0923-7534

VL - 12

SP - 1663

EP - 1666

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -